MTA2 Antibody

INQUIRY

CAT. NO.: AMA-0654

Target Information
UniProt ID	O94776

Product Details
Size	100 µL
Reactivity	Human, Mouse, Rat, Monkey
Storage	Store at -20°C. Do not aliquot the antibody.
Purification	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro602 of human MTA2 protein. Antibodies are purified by peptide affinity chromatography.

Usage
Application	WB
Product Usage Information Dilution	Western Blotting (1:1000)
MW (Target)	75 kDa

Background
MTA2 is a component of the NuRD deacetylase complex, which is recruited by MBD3 and modulates the enzymatic activity of the histone deacetylase core MTA2 is highly related to MTA1, but both proteins exist in biologically distinct complexes, with MTA2 being associated with complexes containing Sin3a and CHD4 MTA2 has been shown to bind ERα and repress its activity and contributes to estradiol- and tamoxifen-resistant breast cancers Indeed, the MTA proteins are critical regulators of many biological functions in both cancer and non-cancer settings MTA2 upregulation has been reported in a multitude of cancers, including hepatocellular carcinomas, colorectal cancers, gastric cancers, and esophageal cancers. MTA2 has also been described in B cell development, where it interacts with Aiolos and Ikaros to control target genes.

Background

MTA2 is a component of the NuRD deacetylase complex, which is recruited by MBD3 and modulates the enzymatic activity of the histone deacetylase core MTA2 is highly related to MTA1, but both proteins exist in biologically distinct complexes, with MTA2 being associated with complexes containing Sin3a and CHD4 MTA2 has been shown to bind ERα and repress its activity and contributes to estradiol- and tamoxifen-resistant breast cancers Indeed, the MTA proteins are critical regulators of many biological functions in both cancer and non-cancer settings MTA2 upregulation has been reported in a multitude of cancers, including hepatocellular carcinomas, colorectal cancers, gastric cancers, and esophageal cancers. MTA2 has also been described in B cell development, where it interacts with Aiolos and Ikaros to control target genes.

Our customers have direct access to our experts and give timely feedback to any online inquiries. If you are interested in our products, please contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.